Filing Details

Accession Number:
0001127602-24-008499
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-05 16:04:13
Reporting Period:
2024-03-01
Accepted Time:
2024-03-05 16:04:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1707000 Eugene Timothy Sullivan C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-01 6,000 $10.03 99,338 No 4 M Direct
Common Stock Disposition 2024-03-01 4,000 $62.86 95,338 No 4 S Direct
Common Stock Disposition 2024-03-01 2,000 $63.95 93,338 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-03-01 6,000 $0.00 6,000 $10.03
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
261,903 2027-10-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 56,232 Indirect The Timothy E Sullivan Irrevocable Trust of 2023
Footnotes
  1. The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
  2. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/1/23.
  3. This option was granted on October 18, 2017 and fully vested.